NEW DELHI: Integrated diagnostic chain Suraksha Diagnostic Ltd on Thursday mentioned it has mobilised Rs 254 crore from anchor investors, a day earlier than opening of its preliminary share-sale for public subscription. The prime anchor investors within the IPO included Nippon India Mutual Fund, Kotak MF, Aditya Birla Sun Life MF, Quant MF and Carnelian Bharat Amritkaal Fund, in line with a round uploaded on BSE’s web site.
The firm has allotted 57.57 lakh fairness shares to 16 funds at Rs 441 apiece, which can also be the higher finish of the worth band. This aggregates the transaction measurement to Rs 254 crore, the round confirmed.
The Rs 846-crore preliminary share-sale will open for public subscription on November 29 and conclude on December 3. The shares might be out there within the value vary of Rs 420 to Rs 441 apiece.
The Kolkata-headquartered firm’s IPO consists of an Offer for Sale (OFS) of 19,189,330 fairness shares price Rs 846.25 crore, on the higher finish of the worth band, by promoters and investor shareholders, with no recent situation element.
Under the OFS, promoters Somnath Chatterjee, Ritu Mittal, and Satish Kumar Verma; and investors OrbiMed Asia II Mauritius Ltd, Munna Lal Kejriwal and Santosh Kumar Kejriwal will offload shares.
Since the problem is totally an OFS, the corporate won’t obtain any proceeds and all of the funds will go to the promoting shareholders.
Explaining the explanation for going public, the corporate mentioned it’s aimed toward reaching the profit of itemizing fairness shares on the inventory exchanges and finishing up OFS for the promoting shareholders.
At the higher finish of the worth band, the corporate’s market capitalisation stands at round Rs 2,300 crore.
Suraksha Diagnostic gives a one-stop built-in resolution for pathology and radiology testing and medical session providers to its clients by means of its in depth operational community, consisting of a flagship central reference laboratory, 8 satellite tv for pc laboratories and 194 buyer touchpoints which embody 48 diagnostic centres, and 146 pattern assortment centres (primarily franchised), throughout West Bengal, Bihar, Assam and Meghalaya as of March 31, 2024.
During fiscal 2024, it carried out about 5.98 million checks serving roughly 1.14 million sufferers.
Half of the problem measurement has been reserved for certified institutional consumers (QIBs), 35 per cent for retail investors and the remaining 10 per cent for non-institutional investors.
ICICI Securities Ltd, Nuvama Wealth Management Ltd and SBI Capital Markets Ltd are the book-running lead managers to the problem. The fairness shares are anticipated to be listed on BSE and NSE on December 6.
